Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients with Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase‐R)

Toru Okuyama,Kazuhiro Yoshiuchi,Asao Ogawa,Satoru Iwase,Naosuke Yokomichi,Akihiro Sakashita,Keita Tagami,Keiichi Uemura,Rika Nakahara,Tatsuo Akechi,Hirofumi Abo,Nobuya Akizuki,Koji Amano,Daisuke Fujisawa,Shingo Hagiwara,Takeshi Hirohashi,Takayuki Hisanaga,Kengo Imai,Shuji Inada,Satoshi Inoue,Shinichiro Inoue,Aio Iwata,Keisuke Kaneishi,Akifumi Kumano,Isseki Maeda,Yoshinobu Matsuda,Takashi Matsui,Yoshihisa Matsumoto,Naoki Matsuo,Kaya Miyajima,Ichiro Mori,sachiyo Morita,Nobuhisa Nakajima,Hiroyuki Nobata,Takuya Odagiri,Ken Shimizu,Yuki Sumazaki Watanabe,Emi Takeuchi,Mari Takeuchi,Ryohei Tatara,Akihiro Tokoro,Megumi Uchida,Hiroaki Watanabe,Ritsuko Yabuki,and Toshihiro Yamauchi

Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients with Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase‐R)

2019

Background. Pharmacotherapy is generally recommended to treat patients with delirium. We sought to describe the current practice, effectiveness, and adverse effects of pharmacotherapy for hypoactive delirium in patients with advanced cancer, and to explore predictors of the deterioration of delirium symptoms after starting pharmacotherapy.

Keywords:

Audit study
Cancer
Delirium
Pharmacology
Pharmacotherapy
Physical therapy
Medicine
Intensive care medicine
Haloperidol
Sedation
palliative care
Pharmacovigilance
Adverse effect
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations